Payment overview · 2025
General Payments
$959.43
49 reported records · 15 companies
Healthcare provider profile · identity verified
Michelle Lynn Plaster, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MONROE, GA · NPI 1073762720
Verified facts
What the public records show
CMS Open Payments records show Michelle Lynn Plaster, M.D. received $959.43 in general payments during 2025 across 49 reported records.
Novo Nordisk Inc accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aptiom by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $322.13 | 33.6% | 18 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $101.38 | 10.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.77 | 7.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $70.10 | 7.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.61 | 6.4% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $56.90 | 5.9% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $54.61 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.95 | 5.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.96 | 4.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.04 | 3.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.81 | 2.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.56 | 2.1% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $18.10 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.78 | 1.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.73 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $959.43 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $204.59 | 11 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $101.38 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $70.10 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $56.90 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $54.61 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.68 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.68 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.96 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.95 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 47 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 117 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 92 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 176 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 340 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
92 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
117 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
176 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
340 | 77 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
47 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1059 | 320 |
| Amlodipine Besylate | Amlodipine Besylate | 838 | 256 |
| Levothyroxine Sodium | Levothyroxine Sodium | 767 | 212 |
| Lisinopril | Lisinopril | 663 | 193 |
| Omeprazole | Omeprazole | 602 | 178 |
| Losartan Potassium | Losartan Potassium | 560 | 166 |
| Gabapentin | Gabapentin | 485 | 158 |
| Sertraline Hcl | Sertraline Hcl | 466 | 124 |
| Pravastatin Sodium | Pravastatin Sodium | 446 | 131 |
| Metformin Hcl | Metformin Hcl | 428 | 129 |
| Prednisone | Prednisone | 421 | 285 |
| Hydrochlorothiazide | Hydrochlorothiazide | 397 | 119 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 352 | 166 |
| Ozempic | Semaglutide | 340 | 77 |
| Trazodone Hcl | Trazodone Hcl | 337 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 103 |
| Azithromycin | Azithromycin | 315 | 266 |
| Metoprolol Tartrate | Metoprolol Tartrate | 312 | 86 |
| Famotidine | Famotidine | 298 | 82 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 285 | 232 |
| Furosemide | Furosemide | 285 | 101 |
| Bupropion Xl | Bupropion Hcl | 282 | 80 |
| Metformin Hcl Er | Metformin Hcl | 282 | 97 |
| Montelukast Sodium | Montelukast Sodium | 281 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 89 |
| Fluticasone Propionate | Fluticasone Propionate | 253 | 101 |
| Potassium Chloride | Potassium Chloride | 253 | 71 |
| Meloxicam | Meloxicam | 240 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 56 |
| Simvastatin | Simvastatin | 223 | 68 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 213 | 62 |
| Carvedilol | Carvedilol | 212 | 63 |
| Methylprednisolone | Methylprednisolone | 203 | 179 |
| Diclofenac Sodium | Diclofenac Sodium | 195 | 61 |
| Fluoxetine Hcl | Fluoxetine Hcl | 177 | 55 |
| Glipizide | Glipizide | 176 | 53 |
| Mounjaro | Tirzepatide | 176 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 175 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 148 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 148 | 49 |
| Ondansetron Odt | Ondansetron | 147 | 92 |
| Mirtazapine | Mirtazapine | 146 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 35 |
| Eliquis | Apixaban | 142 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 43 |
| Amitriptyline Hcl | Amitriptyline Hcl | 136 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 133 | 28 |
| Alendronate Sodium | Alendronate Sodium | 131 | 46 |
| Fluconazole | Fluconazole | 131 | 80 |
| Ezetimibe | Ezetimibe | 130 | 42 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 125 | 89 |
| Donepezil Hcl | Donepezil Hcl | 119 | 35 |
| Jardiance | Empagliflozin | 119 | 30 |
| Chlorthalidone | Chlorthalidone | 117 | 29 |
| Farxiga | Dapagliflozin Propanediol | 117 | 29 |
| Myrbetriq | Mirabegron | 115 | 24 |
| Allopurinol | Allopurinol | 114 | 37 |
| Buspirone Hcl | Buspirone Hcl | 109 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 109 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 26 |
| Spironolactone | Spironolactone | 109 | 28 |
| Clonidine Hcl | Clonidine Hcl | 103 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 34 |
| Tramadol Hcl | Tramadol Hcl | 97 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 50 |
| Synthroid | Levothyroxine Sodium | 95 | 23 |
| Alprazolam | Alprazolam | 94 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 23 |
| Linzess | Linaclotide | 92 | 28 |
| Nystatin | Nystatin | 90 | 48 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 76 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 88 | 69 |
| Estradiol | Estradiol | 86 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 86 | 79 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 86 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 23 |
| Finasteride | Finasteride | 80 | 24 |
| Januvia | Sitagliptin Phosphate | 80 | 22 |
| Meclizine Hcl | Meclizine Hcl | 79 | 45 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 74 | 74 |
| Ibuprofen | Ibuprofen | 73 | 33 |
| Valacyclovir | Valacyclovir Hcl | 71 | 36 |
| Atenolol | Atenolol | 70 | 21 |
| Glipizide Er | Glipizide | 70 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 22 |
| Acyclovir | Acyclovir | 68 | 26 |
| Propranolol Hcl | Propranolol Hcl | 68 | 15 |
| Fenofibrate | Fenofibrate | 67 | 19 |
| Temazepam | Temazepam | 67 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | 13 |
| Rybelsus | Semaglutide | 63 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 18 |
| Glimepiride | Glimepiride | 60 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 21 |
| Cephalexin | Cephalexin | 58 | 52 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 22 |
| Prolia | Denosumab | 57 | 41 |
| Valsartan | Valsartan | 56 | 19 |
| Amoxicillin | Amoxicillin | 53 | 44 |
| Lorazepam | Lorazepam | 53 | 14 |
| Mupirocin | Mupirocin | 53 | 38 |
| Lovastatin | Lovastatin | 52 | 18 |
| Clonazepam | Clonazepam | 50 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 18 |
| Trulicity | Dulaglutide | 49 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 47 | 47 |
| Sucralfate | Sucralfate | 46 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 13 |
| Celecoxib | Celecoxib | 42 | 12 |
| Promethazine Hcl | Promethazine Hcl | 42 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 14 |
| Baclofen | Baclofen | 39 | 23 |
| Benazepril Hcl | Benazepril Hcl | 38 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 12 |
| Pregabalin | Pregabalin | 35 | 15 |
| Cefdinir | Cefdinir | 34 | 31 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Metronidazole | Metronidazole | 29 | 25 |
| Hydrocortisone | Hydrocortisone | 28 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Colchicine | Colchicine | 26 | 19 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Progesterone | Progesterone, Micronized | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 13 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Vienva | Levonorgestrel/Ethin.Estradiol | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Ramipril | Ramipril | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Incassia | Norethindrone | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | 11 |
| Latanoprost | Latanoprost | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $959.43 · 49 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Korlym, LINZESS, Leqembi, MOUNJARO, NEFFY, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, Tymlos, Wegovy, Xhance, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error